COVID-19 in adult acute myeloid leukemia patients: a long-term followup study from the European Hematology Association survey (EPICOVIDEHA)
Archive ouverte
Marchesi, Francesco | Salmanton-García, Jon | Emarah, Ziad | Piukovics, Klára | Nucci, Marcio | López-García, Alberto | Ráčil, Zdeněk | Farina, Francesca | Popova, Marina | Zompi, Sofia | Audisio, Ernesta | Ledoux, Marie-Pierre | Verga, Luisa | Weinbergerová, Barbora | Szotkovski, Tomas | da Silva, Maria Gomes | Fracchiolla, Nicola | de Jonge, Nick | Collins, Graham | Marchetti, Monia | Magliano, Gabriele | García-Vidal, Carolina | Biernat, Monika | van Doesum, Jaap | Machado, Marina | Demirkan, Fatih | Al-Khabori, Murtadha | Žák, Pavel | Víšek, Benjamín | Stoma, Igor | Méndez, Gustavo-Adolfo | Maertens, Johan | Khanna, Nina | Espigado, Ildefonso | Dragonetti, Giulia | Fianchi, Luana | del Principe, Maria Ilaria | Cabirta, Alba | Ormazabal-Vélez, Irati | Jaksic, Ozren | Buquicchio, Caterina | Bonuomo, Valentina | Batinić, Josip | Omrani, Ali | Lamure, Sylvain | Finizio, Olimpia | Fernández, Noemí | Falces-Romero, Iker | Blennow, Ola | Bergantim, Rui | Ali, Natasha | Win, Sein | van Praet, Jens | Tisi, Maria Chiara | Shirinova, Ayten | Schönlein, Martin | Prattes, Juergen | Piedimonte, Monica | Petzer, Verena | Navrátil, Milan | Kulasekararaj, Austin | Jindra, Pavel | Sramek, Jiří | Glenthøj, Andreas | Fazzi, Rita | de Ramón-Sánchez, Cristina | Cattaneo, Chiara | Calbacho, Maria | Bahr, Nathan | El-Ashwah, Shaimaa | Cordoba, Raul | Hanakova, Michaela | Zambrotta, Giovanni | Sciumè, Mariarita | Booth, Stephen | Rodrigues, Raquel Nunes | Sacchi, Maria Vittoria | García-Poutón, Nicole | Martín-González, Juan-Alberto | Khostelidi, Sofya | Gräfe, Stefanie | Rahimli, Laman | Ammatuna, Emanuele | Busca, Alessandro | Corradini, Paolo | Hoenigl, Martin | Klimko, Nikolai | Koehler, Philipp | Pagliuca, Antonio | Passamonti, Francesco | Cornely, Oliver | Pagano, Livio
Edité par
CCSD ; Ferrata Storti Foundation -
International audience.
Patients with acute myeloid leukemia (AML) are at high risk of mortality from coronavirus disease 2019 (COVID-19). The optimal management of AML patients with COVID-19 has not been established. Our multicenter study included 388 adult AML patients with COVID-19 diagnosis between February 2020 and October 2021. The vast majority were receiving or had received AML treatment in the prior 3 months. COVID-19 was severe in 41.2% and critical in 21.1% of cases. The chemotherapeutic schedule was modified in 174 patients (44.8%), delayed in 68 and permanently discontinued in 106. After a median follow-up of 325 days, 180 patients (46.4%) had died; death was attributed to COVID-19 (43.3%), AML (26.1%) or to a combination of both (26.7%), whereas in 3.9% of cases the reason was unknown. Active disease, older age, and treatment discontinuation were associated with death, whereas AML treatment delay was protective. Seventy-nine patients had a simultaneous AML and COVID-19 diagnosis, with an improved survival when AML treatment could be delayed (80%; p
